Brightline (BI1403-0008): brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma.

EORTC QOL: Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients

FaR-RMS: An overarching study for children and adults with frontline and relapsed rhabdomyosarcoma

GSK 7011618 SCOOP: Phase I Niraparib and Dostarlimab in paediatric patients with recurrent or refractory solid tumours

ICONIC: Improving outcomes through collaboration in osteosarcoma

ImmunoSARC :Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas

KINDRED ASSG: The International Sarcoma Kindred study: A global multi-site prospective cancer genetics study

PREDICT B: Predicting radiotherapy response, toxicities and quality of life related functional  outcome in soft tissue sarcoma of the extremities: a prospective observational cohort study

rEECUr: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma

RINGSIDE:  A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

SMPaeds: Stratified medicine paediatrics: genomic characterisation of relapsed paediatric cancers for diagnostics and stratified therapy

SPEARHEAD 1: A phase II single arm open-label clinical trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

TOLERANCE (EORTC-1976): A 3 arm randomized study on health-related quality of life of elderly patients with advanced soft tissue sarcoma undergoing doxorubicin alone three weekly or doxorubicin weekly or cyclophosphamide plus prednisolone treatment (TOLERANCE)

Sometimes there may be other trials open - it is always worth asking your doctor.